About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

COMPLETEDPhase 1

A Study to Understand the Effect of Multiple Ascending Doses of PF-07293893 in Healthy Adult Participants

A PHASE 1, MULTI-PART RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF MULTIPLE ASCENDING ORAL DOSES OF PF-07293893 IN HEALTHY ADULT PARTICIPANTS

NCT06177457•Pfizer

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Healthy Participants

Interventions

PF-07293893

Placebo

+1 more

Locations

3

United States

Locations (3)

Pfizer Clinical Research Unit - New Haven

New Haven, Connecticut, United States

Yale University/Magnetic Resonance Research Center (MRRC)

New Haven, Connecticut, United States

Pfizer Clinical Research Unit - Brussels

Brussels, Bruxelles-capitale, Région de, Belgium

Key Dates

Start Date

December 20, 2023

Primary Completion Date

December 2, 2024

Completion Date

December 2, 2024

Last Updated

December 18, 2024

Related Studies

RECRUITINGPhase 1

A 2-part, Phase 1b Clinical Study Designed to Evaluate the Safety, PK, and Efficacy of CRB-913 in Participants With Obesity

NCT07310901

Obese But Otherwise Healthy Participants

RECRUITINGPhase 1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Autoimmune Dermatological Diseases

NCT06342713

Healthy ParticipantsHealthy Subjects+5 more

RECRUITINGPhase 1

Study of BW-50218 in Healthy Participants

NCT07401472

Healthy Participants Study

RECRUITINGPhase 1

A Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of SYH2085

NCT07412353

Healthy Participants

RECRUITINGPhase 1/2

A Phase I/II, Dose-finding Study to Assess the Safety, Reactogenicity, and Immunogenicity of a Broadly Protective Sarbecovirus Vaccine (GBP511) in Healthy Adults.

NCT07280858

Healthy ParticipantsSarbecovirus

RECRUITINGPhase 1

A Study to Evaluate Single and Multiple Doses of TLC-1180 in Healthy Subjects

NCT07300189

Healthy Participants

View all related studies

Sponsors

Lead Sponsor

Pfizer

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 18, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions